At a Glance OHSU is developing a vaccine for West Nile Virus that could reach human clinical trials within 3 years. To date, there is no existing approved human vaccine for West Nile. The West Nile Virus vaccine will be created through an exciting new ...

The Oregon National Primate Research Center at Oregon Health & Science University has received another clean bill of health from the United States Department of Agriculture. Approximately twice a year, the USDA conducts unannounced inspections of ...

The Spine Center is using state-of the-art computer and Internet technology to track past and current patients to determine which treatments have the best odds of success for a wide variety of injuries. "When compared to other orthopaedic injuries, ...

WHAT: A wall of people who have very personal experiences with heart disease will mark the starting line at the annual American Heart Association's Start! Heart and Stroke Walk. Some walk with new hearts, some with ventricular assist devices that will ...

Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; ...

v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} Normal 0 false false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable ...

Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; ...

The Oregon Health & Science University Knight Cancer Institute will evaluate whether the state-of-the-art image-guidance system called Calypso® (Calypso® Medical, Seattle, Wash.) is as effective in delivering highly precise radiation therapy to head ...

A new drug called MDV3100 has shown significant promise in lowering the prostate specific antigen (PSA) levels ‑ a marker for tumor growth ‑ in men with advanced prostate cancer who have no other option for cure. The drug has also been shown to shrink ...